Last reviewed · How we verify

NCT06145360

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Completed Phase 4 Last updated 8 April 2024
What this trial tests

Phase 4 trial testing Empagliflozin 10 MG in Glucose Metabolism Disorders in 150 participants. Completed in 1 March 2024.

Timeline
1 December 2023
Primary endpoint
1 March 2024
1 March 2024

Quick facts

Lead sponsorSINA Health Education and Welfare Trust
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingdouble
Primary purposetreatment
Enrollment150
Start date1 December 2023
Primary completion1 March 2024
Estimated completion1 March 2024
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

SINA Health Education and Welfare Trust — full company profile →

Who can join

Adults 20 to 70, any sex, with Glucose Metabolism Disorders or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this study is to assess the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+Dipeptidyl peptidase 4 (DPP-4) inhibitors in poorly controlled type 2 diabetes mellitus (T2DM) patients. The study seeks to evaluate its effect on achieving glycemic goals in this patient population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Empagliflozin 10 MG

Trials testing the same drug.

Other recruiting trials for Glucose Metabolism Disorders

Currently open trials in the same condition.

Other SINA Health Education and Welfare Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06145360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing